BMO Capital Markets reiterated their outperform rating on shares of AveXis, Inc. (NASDAQ:AVXS) in a report released on Thursday. The firm currently has a $130.00 price target on the stock, up from their previous price target of $123.00.

Several other research analysts have also weighed in on the stock. Barclays PLC started coverage on shares of AveXis in a report on Wednesday, September 6th. They set an overweight rating and a $124.00 price objective for the company. Nomura started coverage on shares of AveXis in a report on Monday, August 28th. They set a reduce rating and a $52.00 price objective for the company. Instinet started coverage on shares of AveXis in a report on Tuesday, August 29th. They set a reduce rating and a $52.00 price objective for the company. Zacks Investment Research raised shares of AveXis from a sell rating to a hold rating in a report on Thursday, September 7th. Finally, Jefferies Group LLC reissued a buy rating on shares of AveXis in a report on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $107.38.

AveXis (AVXS) traded up 0.36% during trading on Thursday, reaching $104.39. 261,955 shares of the company’s stock traded hands. AveXis has a 1-year low of $43.06 and a 1-year high of $106.00. The stock has a 50-day moving average price of $94.94 and a 200 day moving average price of $83.74. The stock’s market capitalization is $3.33 billion.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($1.10). During the same period in the prior year, the business earned ($0.68) EPS. Equities research analysts expect that AveXis will post ($6.22) earnings per share for the current year.

WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/10/15/avexis-inc-avxs-earns-outperform-rating-from-bmo-capital-markets.html.

In other news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $91.52, for a total value of $162,905.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $162,905.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The disclosure for this sale can be found here. Insiders sold a total of 20,340 shares of company stock valued at $2,023,896 over the last ninety days. Company insiders own 18.60% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Nationwide Fund Advisors lifted its position in AveXis by 9.0% in the 1st quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after purchasing an additional 284 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in AveXis by 2.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock valued at $1,721,000 after purchasing an additional 598 shares during the last quarter. American International Group Inc. lifted its position in AveXis by 26.7% in the 1st quarter. American International Group Inc. now owns 3,521 shares of the company’s stock valued at $268,000 after purchasing an additional 742 shares during the last quarter. Swiss National Bank lifted its position in AveXis by 3.0% in the 1st quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after purchasing an additional 800 shares during the last quarter. Finally, Seven Bridges Advisors LLC lifted its position in AveXis by 49.4% in the 2nd quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock valued at $210,000 after purchasing an additional 846 shares during the last quarter. Hedge funds and other institutional investors own 94.71% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.